Table 2 Association of overall response rate with IMDC favorable-, intermediate-, and poor-risk patients.

From: Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study

 

All (n = 118)

Favorable (n = 27)

Intermediate (n = 60)

Poor (n = 31)

Best response, n (%)

CR

13 (11.0)

8 (29.6)

4 (6.7)

1 (3.2)

PR

69 (58.5)

11 (40.7)

39 (66.7)

19 (58.1)

SD

31 (26.3)

6 (22.2)

16 (25.0)

9 (32.3)

PD

5 (4.2)

2 (7.4)

1 (1.7)

2 (6.5)

ORR

n (%)

82 (69.5)

19 (70.4)

43 (71.7)

20 (64.5)

DCR

    

n (%)

113 (95.8)

25 (92.6)

59 (98.3)

29 (93.5)

  1. DCR; disease control rate, ORR; objective response rate.
Back to article page